We aimed to develop an @entity3206 model, using @entity3216 -induced @entity4089 in common marmosets. The serum @entity69060 level gradually increased during the twice-daily administration of @entity3216 and reached a plateau after 4 days. @entity3216 produced as big a response at 10 mg kg(-1) as at 50 mg kg(-1). In this study, the length of the ovarian cycle was approximately 30 days in normal common marmosets. Serum @entity1420 and @entity53 levels showed no consistent change during the first 2 months of treatment with @entity3216 . When treatment with @entity3216 had been continued for more than 2 months, serum @entity1420 and @entity53 levels fell to within the range seen in the follicular phase of the normal cycle and absence of ovulation was recognized by laparoscopy. A single oral administration of @entity9229 (at doses between 0.01 and 0.1 mg kg(-1)) dose dependently reduced the elevated serum @entity69060 level. @entity2847 (at an oral dose of 10 mg kg(-1)) also reduced the serum @entity69060 level at 4 and 8 h after its administration. With @entity2847 , the @entity69060 level had recovered at 24 h, but with @entity9229 at doses of 0.05 mg kg(-1) or more, it had still not recovered at 48 h. In anovulatory @entity7533 , oral administration of @entity9229 at a daily dose of 0.05 mg kg(-1) restored ovarian function and resulted in ovulation in 100% of the group (following a reduction in the serum @entity69060 level). @entity2847 at a daily oral dose of 10 mg kg(-1) resulted in ovulation in 67% of the group, but this dose was about 200 times higher than the dose of @entity9229 . We could produce an anovulatory model induced by @entity3216 repeatedly administered over a long time period. It is suggested that, in this anovulatory model in @entity7533 , @entity9229 has a potent and long-lasting action as a @entity935 D2 receptor agonist, and thus could be a useful drug for the treatment of @entity6726 and @entity3206 .

New XXXX and @entity3206 model in @entity7533 ( @entity7533 ) and effect of @entity9229 .

@entity4089 :: ('MESH:D006966', 'Disease') :: ['hyperprolactinemia'] @entity69060 :: ('100413643', 'Gene') :: ['prolactin'] @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine', 'Bromocriptine'] @entity6726 :: ('MESH:D005687', 'Disease') :: ['galactorrhea'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['cabergoline'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity3206 :: ('MESH:D000858', 'Disease') :: ['hyperprolactinemic amenorrhea and/or anovulation', 'anovulation'] @entity3216 :: ('MESH:D013469', 'Chemical') :: ['Sulpiride', 'sulpiride'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity7533 :: ('9483', 'Species') :: ['common marmosets']
@entity4089 :: (MESH:D006966,Disease) :: ['hyperprolactinemia']
